Transgenic pigs produce functional human factor VIII in milk

Rekha K. Paleyanda, William H. Velander, Timothy K. Lee, Dorothea H. Scandella, Francis C. Gwazdauskas, James W. Knight, Leon W. Hoyer, William N. Drohan, Henryk Lubon

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant FVIII (rFVIII) prepared from mammalian cell culture. The cost of highly purified FVIII or rFVIII is a major factor in hemophilia therapy and restricts prophylaxis. We have sought to generate a new source of rFVIII by targeting expression of the human FVIII cDNA to the mammary gland of transgenic pigs using the regulatory sequences of the mouse whey acidic protein gene. The identity of processed heterodimeric rFVIII was confirmed using specific antibodies, by thrombin digestion and activity assays. The secretion of as much as 2.7 μ-g/ml of rFVIII in milk was over tenfold higher than in normal plasma. Up to 0.62 U/ml of rFVIII was detected in an assay in which rFVIII restored normal clotting activity to FVIII-deficient human plasma.

Original languageEnglish (US)
Pages (from-to)971-975
Number of pages5
JournalNature Biotechnology
Volume15
Issue number10
DOIs
StatePublished - Oct 1997

Fingerprint

Plasma (human)
Factor VIII
Human engineering
Assays
Milk
Swine
Hemophilia A
Coagulation
Cell culture
Antibodies
Genes
Proteins
Plasmas
Human Mammary Glands
Thrombin
Costs
Digestion
Complementary DNA
Cell Culture Techniques
Hemorrhage

Keywords

  • Blood coagulation
  • Mammary gland
  • Transgenic animals

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Molecular Medicine
  • Biomedical Engineering

Cite this

Paleyanda, R. K., Velander, W. H., Lee, T. K., Scandella, D. H., Gwazdauskas, F. C., Knight, J. W., ... Lubon, H. (1997). Transgenic pigs produce functional human factor VIII in milk. Nature Biotechnology, 15(10), 971-975. https://doi.org/10.1038/nbt1097-971

Transgenic pigs produce functional human factor VIII in milk. / Paleyanda, Rekha K.; Velander, William H.; Lee, Timothy K.; Scandella, Dorothea H.; Gwazdauskas, Francis C.; Knight, James W.; Hoyer, Leon W.; Drohan, William N.; Lubon, Henryk.

In: Nature Biotechnology, Vol. 15, No. 10, 10.1997, p. 971-975.

Research output: Contribution to journalArticle

Paleyanda, RK, Velander, WH, Lee, TK, Scandella, DH, Gwazdauskas, FC, Knight, JW, Hoyer, LW, Drohan, WN & Lubon, H 1997, 'Transgenic pigs produce functional human factor VIII in milk', Nature Biotechnology, vol. 15, no. 10, pp. 971-975. https://doi.org/10.1038/nbt1097-971
Paleyanda RK, Velander WH, Lee TK, Scandella DH, Gwazdauskas FC, Knight JW et al. Transgenic pigs produce functional human factor VIII in milk. Nature Biotechnology. 1997 Oct;15(10):971-975. https://doi.org/10.1038/nbt1097-971
Paleyanda, Rekha K. ; Velander, William H. ; Lee, Timothy K. ; Scandella, Dorothea H. ; Gwazdauskas, Francis C. ; Knight, James W. ; Hoyer, Leon W. ; Drohan, William N. ; Lubon, Henryk. / Transgenic pigs produce functional human factor VIII in milk. In: Nature Biotechnology. 1997 ; Vol. 15, No. 10. pp. 971-975.
@article{becde20da1b84e41ab54e63133b2de6f,
title = "Transgenic pigs produce functional human factor VIII in milk",
abstract = "Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant FVIII (rFVIII) prepared from mammalian cell culture. The cost of highly purified FVIII or rFVIII is a major factor in hemophilia therapy and restricts prophylaxis. We have sought to generate a new source of rFVIII by targeting expression of the human FVIII cDNA to the mammary gland of transgenic pigs using the regulatory sequences of the mouse whey acidic protein gene. The identity of processed heterodimeric rFVIII was confirmed using specific antibodies, by thrombin digestion and activity assays. The secretion of as much as 2.7 μ-g/ml of rFVIII in milk was over tenfold higher than in normal plasma. Up to 0.62 U/ml of rFVIII was detected in an assay in which rFVIII restored normal clotting activity to FVIII-deficient human plasma.",
keywords = "Blood coagulation, Mammary gland, Transgenic animals",
author = "Paleyanda, {Rekha K.} and Velander, {William H.} and Lee, {Timothy K.} and Scandella, {Dorothea H.} and Gwazdauskas, {Francis C.} and Knight, {James W.} and Hoyer, {Leon W.} and Drohan, {William N.} and Henryk Lubon",
year = "1997",
month = "10",
doi = "10.1038/nbt1097-971",
language = "English (US)",
volume = "15",
pages = "971--975",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Transgenic pigs produce functional human factor VIII in milk

AU - Paleyanda, Rekha K.

AU - Velander, William H.

AU - Lee, Timothy K.

AU - Scandella, Dorothea H.

AU - Gwazdauskas, Francis C.

AU - Knight, James W.

AU - Hoyer, Leon W.

AU - Drohan, William N.

AU - Lubon, Henryk

PY - 1997/10

Y1 - 1997/10

N2 - Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant FVIII (rFVIII) prepared from mammalian cell culture. The cost of highly purified FVIII or rFVIII is a major factor in hemophilia therapy and restricts prophylaxis. We have sought to generate a new source of rFVIII by targeting expression of the human FVIII cDNA to the mammary gland of transgenic pigs using the regulatory sequences of the mouse whey acidic protein gene. The identity of processed heterodimeric rFVIII was confirmed using specific antibodies, by thrombin digestion and activity assays. The secretion of as much as 2.7 μ-g/ml of rFVIII in milk was over tenfold higher than in normal plasma. Up to 0.62 U/ml of rFVIII was detected in an assay in which rFVIII restored normal clotting activity to FVIII-deficient human plasma.

AB - Deficiency or abnormality of coagulation factor VIII (FVIII) causes a bleeding disorder called hemophilia A. Treatment involves FVIII concentrates prepared from pooled human plasma or recombinant FVIII (rFVIII) prepared from mammalian cell culture. The cost of highly purified FVIII or rFVIII is a major factor in hemophilia therapy and restricts prophylaxis. We have sought to generate a new source of rFVIII by targeting expression of the human FVIII cDNA to the mammary gland of transgenic pigs using the regulatory sequences of the mouse whey acidic protein gene. The identity of processed heterodimeric rFVIII was confirmed using specific antibodies, by thrombin digestion and activity assays. The secretion of as much as 2.7 μ-g/ml of rFVIII in milk was over tenfold higher than in normal plasma. Up to 0.62 U/ml of rFVIII was detected in an assay in which rFVIII restored normal clotting activity to FVIII-deficient human plasma.

KW - Blood coagulation

KW - Mammary gland

KW - Transgenic animals

UR - http://www.scopus.com/inward/record.url?scp=0030771837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030771837&partnerID=8YFLogxK

U2 - 10.1038/nbt1097-971

DO - 10.1038/nbt1097-971

M3 - Article

C2 - 9335047

AN - SCOPUS:0030771837

VL - 15

SP - 971

EP - 975

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 10

ER -